An early look at FDA trends

By Maureen Martino and Tracy Staton

It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a significant impact the U.S. as well as the world markets, so it's always wise to keep an eye on happenings at the FDA.

In that vein, here's an early look at four FDA trends we've identified so far this year. We'll see how these play out by the end of the year.

Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.